Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.60 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30277147 | 1.00 | HTT (0.71) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL24710086 | 1.00 | HTT (0.71) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL29179558 | 1.00 | HTT (0.71) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL9011724 | 0.87 | HTT (0.75) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL30852969 | 0.86 | HTT (0.65) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL5652155 | 0.86 | HTT (0.65) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL29179603 | 0.86 | HTT (0.65) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL1568062 | 0.84 | KMT2A (0.71) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL15028545 | 0.84 | HTT (0.66) | HTTKMT2AMEN1ALDH1A1EPHX1 | |
| SCHEMBL2406255 | 0.83 | HTT (1.00) | HTTKMT2AMEN1ALDH1A1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-09 | — | — | US | disclosed |
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | HTT 4160/4885KMT2A 2364/4885MEN1 3185/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | HTT 4160/4885KMT2A 2364/4885MEN1 3185/4885 |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | ACE, ACE2, TMPRSS2 | HTT 4160/4885KMT2A 2364/4885MEN1 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.